Loading...
•
Mar 31, 2023
Dynavax Q1 2023 Earnings Report
Reported financial results for the quarter ended March 31, 2023.
Key Takeaways
Dynavax reported a first quarter 2023 total revenue of $46.9 million, which includes HEPLISAV-B vaccine product revenue of $43.5 million, a 109% increase compared to the first quarter of 2022. The company's cash and investments were $652 million at quarter end and expects positive free cash flow in 2023.
HEPLISAV-B vaccine net product revenue increased 109% year-over-year to $43.5 million in the first quarter of 2023
Reaffirming HEPLISAV-B net product revenue guidance for full year 2023 of between $165–$185 million, representing annual revenue growth of 30-47%
Strengthened balance sheet with cash and investments of $652 million at quarter end
Expects positive free cash flow in 2023
Forward Guidance
Full year 2023 financial guidance is reiterated and consists of the following expectations:
Positive Outlook
- HEPLISAV-B net product revenue between approximately $165 - $185 million
- Research and development expenses between approximately $55 - $70 million
- Selling, general and administrative expenses between approximately $135 - $155 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...